Covered recipient · General Payments record
NADIA I KIHICZAK
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$5,347.88
- Reported across 178 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $435.75 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $109.38 | 2 |
| PFIZER INC. | $85.90 | 4 |
| Regeneron Healthcare Solutions, Inc. | $39.57 | 1 |
| LEO Pharma Inc. | $33.57 | 1 |
| Lilly USA, LLC | $29.84 | 1 |
| Dermavant Sciences, Inc. | $27.29 | 1 |
| Incyte Corporation | $26.09 | 1 |
| ABBVIE INC. | $23.38 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $21.30 | 1 |
| E.R. Squibb & Sons, L.L.C. | $20.51 | 1 |
| Galderma Laboratories, L.P. | $18.92 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $23.38 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104069422 | CMS |
| Dermavant Sciences, Inc. | $27.29 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127889714 | CMS |
| E.R. Squibb & Sons, L.L.C. | $20.51 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101443915 | CMS |
| Galderma Laboratories, L.P. | $18.92 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145309060 | CMS |
| GENZYME CORPORATION | $21.21 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140006194 | CMS |
| GENZYME CORPORATION | $88.17 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140006224 | CMS |
| Incyte Corporation | $26.09 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141191815 | CMS |
| LEO Pharma Inc. | $33.57 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152637779 | CMS |
| Lilly USA, LLC | $29.84 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135230179 | CMS |
| PFIZER INC. | $21.61 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131100213 | CMS |
| PFIZER INC. | $20.13 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131124103 | CMS |
| PFIZER INC. | $21.66 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131633684 | CMS |
| PFIZER INC. | $22.50 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131022611 | CMS |
| Regeneron Healthcare Solutions, Inc. | $39.57 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114087107 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $21.30 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152185893 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.